Scrip Awards 2020
The 16th Annual Scrip Awards, 2 December 2020, London
Deadline for entries 8 June
Since they began, the Scrip Awards has sought to applaud the essential role that the pharmaceutical, biotech and other allied industries play in improving healthcare. Its trophies span the entire range of industry activities, from new drug launches and clinical trials, to innovative deals, outsourcing and fundraising. In the current climate it’s more important than ever to recognize what has been achieved.
This year, we have introduced a new category – China Biopharma Leadership Award – to reflect the rapid maturing of China’s biopharma sector, thanks to the development of homegrown biopharma companies, CDMOs and increasing investment in the market from global multinational biopharma companies.
Over the past 16 years, the Scrip Awards has carved out a unique place in the industry calendar, with attendees coming from around the world to the prestigious ceremony, which this year will take place in the London Hilton on Park Lane in Mayfair on 2 December.
The deadline for entries is 8 June. Now is the time to prepare your entry and make sure you take your place among the best.
The safety and experience of our customers and teams are always our top priority. As such, we’re closely monitoring developments with COVID-19. We are following all government and health authority advice and are working with our venue partners to put in place a number of enhanced safety and hygiene measures at the Scrip Awardsand ensure a good event for everyone. For any questions, please contact our Lisa Anderberg. We will keep this page updated as the situation changes.
We look forward to seeing you at the Scrip Awards for what is always a great chance to build relationships, make new partnerships and celebrate our industry and its latest achievements.
ICON plc is a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development – from compound selection to Phase I-IV clinical studies.With headquarters in Dublin, Ireland, ICON currently, operates from 97 locations in 38 countries and has approximately 13,100 employees.
CMIC stands for Current Medical Information Center. In 1992, Dr. Kazuo Nakamura founded CMIC as the first Contract Research Organization (CRO) in Japan. CMIC Group is currently the largest clinical CRO in Japan, providing comprehensive services in drug development, clinical trial and clinical site management, clinical to commercial GMP manufacturing, regulatory consulting and contract sales & marketing solutions. We can help pharmaceutical, biotech and medical device companies to enter Japan market, to conduct clinical trials in Asia, or to bridge your drug development and manufacturing needs between the US and Japan. CMIC Group has over 7,000 employees and 25 sites globally.
Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 1,400 customers and partners access the world's most-used platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systèmes company (Euronext Paris: #13065, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at www.medidata.com.
Founded by physicians committed to advancing medical science, Worldwide is out to change how the world experiences CROs – in the best possible way. From early phase and bioanalytical sciences through late phase, post-approval and real-world evidence, we provide world-class, full-service drug development services across a range of therapeutic areas, including central nervous system, cardiovascular, metabolic, immune-mediated inflammatory disorders (IMID), oncology and rare diseases. We never compromise on science or safety. We’re never satisfied with the status quo. We’re the Cure for the Common CRO. http://www.worldwide.com.
WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient solutions. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec’s open-access platform is enabling more than 3,600 collaborators from over 30 countries to improve the health of those in need – and to fulfill our dream that "every drug can be made and every disease can be treated."